TRISALUS LIFE SCIENCES, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.39 USD | -7.49% |
|
-4.48% | +11.12% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 313.4 | 222.4 | 263.6 | - | - |
| Enterprise Value (EV) 1 | 313.4 | 222.4 | 263.6 | 263.6 | 263.6 |
| P/E ratio | -2.51 x | -1.26 x | -5.52 x | -7.19 x | -6.38 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 12 x | 9.14 x | 6.25 x | 4.6 x |
| EV / Revenue | - | 12 x | 9.14 x | 6.25 x | 4.6 x |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | - | -4.39 x | -5.48 x | -6.75 x | -4.74 x |
| FCF Yield | - | -22.8% | -18.2% | -14.8% | -21.1% |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 31,250 | 26,317 | 26,758 | - | - |
| Reference price 2 | 10.03 | 8.450 | 9.850 | 9.850 | 9.850 |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 18.51 | 28.83 | 42.16 | 57.35 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -54.15 | -42.71 | -41.74 | -57.35 |
| Operating Margin | - | -292.53% | -148.15% | -99% | -99.99% |
| Earnings before Tax (EBT) 1 | - | -59.03 | -44.74 | -44.86 | -60.72 |
| Net income 1 | -47.19 | -63.28 | -45.19 | -44.91 | -60.77 |
| Net margin | - | -341.83% | -156.76% | -106.53% | -105.96% |
| EPS 2 | -3.990 | -6.730 | -1.785 | -1.370 | -1.545 |
| Free Cash Flow 1 | - | -50.63 | -48.1 | -39.04 | -55.55 |
| FCF margin | - | -273.53% | -166.85% | -92.6% | -96.85% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5.721 | 6.457 | 6.94 | 7.283 | 8.146 | 9.371 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -14.12 | -11.68 | -10.57 | -10.54 | -9.906 | -11.9 |
| Operating Margin | -246.78% | -180.97% | -152.33% | -144.74% | -121.61% | -126.93% |
| Earnings before Tax (EBT) 1 | -35.51 | -13.22 | -10.99 | -10.96 | -10.33 | -13.08 |
| Net income 1 | -36.31 | -14.02 | -10.99 | -10.96 | -10.38 | -13.08 |
| Net margin | -634.66% | -217.13% | -158.41% | -150.54% | -127.41% | -139.54% |
| EPS 2 | -1.560 | -0.6000 | -0.4400 | -0.4200 | -0.3850 | -0.3900 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/1/24 | 5/15/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -50.6 | -48.1 | -39 | -55.5 |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 1.44 | 2.18 | 2.65 |
| Capex / Sales | - | - | 5% | 5.17% | 4.62% |
| Announcement Date | 4/21/23 | 4/1/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
9.85
USD
Average target price
16
USD
Spread / Average Target
+62.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.12% | 264M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.82% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- TLSI Stock
- Financials TriSalus Life Sciences, Inc.
